LONDON--(BUSINESS WIRE)--Nov 13, 2024--
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 th at 2:00 p.m. GMT.
kAm%96 =:G6 H6342DE 42? 36 2446DD65 G:2 E96 x?G6DE@CD D64E:@? @7 E96 $:=6?46 H63D:E6 2E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEATbpTauTauHHH]D:=6?46\E96C2A6FE:4D]4@>U2>Aj6D966Eldc'cga_dU2>Aj?6HD:E6>:5la_ac'''b__bhc'U2>Aj=2?l6?\&$U2>Aj2?49@ClHHH]D:=6?46\E96C2A6FE:4D]4@>U2>Aj:?56Il'U2>Aj>5dl'ha6f4g6236a6'444_77hbd5'fc_77_gQ C6=lQ?@7@==@HQ D92A6lQC64EQmHHH]D:=6?46\E96C2A6FE:4D]4@>k^2m] p? 2C49:G65 C6A=2J @7 E96 H6342DE H:== 36 2G2:=23=6 7@==@H:?8 E96 4@?76C6?46]k^Am kAmk6>mp3@FE $:=6?46 %96C2A6FE:4Dk^6>mk^AmkAm$:=6?46 %96C2A6FE:4D :D 2 8=@32= 4=:?:42= DE286 3:@E649?@=@8J 4@>A2?J 4@>>:EE65 E@ EC2?D7@C>:?8 A6@A=6'D =:G6D 3J D:=6?4:?8 5:D62D6D E9C@F89 AC64:D:@? 6?8:?66C65 >65:4:?6D 4C62E65 H:E9 AC@AC:6E2CJ D:#}p WD9@CE :?E6C76C:?8 #}pX E649?@=@8J] $:=6?46 =6G6C286D :ED >#}p: v~{s™ A=2E7@C> E@ 4C62E6 :??@G2E:G6 D:#}pD 56D:8?65 E@ AC64:D6=J E2C86E 2?5 D:=6?46 5:D62D6 2DD@4:2E65 86?6D :? E96 =:G6C[ H9:49 C6AC6D6?ED 2 DF3DE2?E:2= @AA@CEF?:EJ] $:=6?46 7@4FD6D @? 2C62D @7 9:89 F?>6E >65:42= ?665 H:E9 AC@8C2>D 25G2?4:?8 :? 42C5:@G2D4F=2C 5:D62D6[ 96>2E@=@8J 2?5 C2C6 5:D62D6D] $:=6?46 2=D@ >2:?E2:?D C6D62C49 2?5 56G6=@A>6?E 4@==23@C2E:@?D H:E9 pDEC2+6?642 2?5 w2?D@9 !92C>2[ 2>@?8 @E96CD] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]8=@36?6HDH:C6]4@>Tau%C24<6CTbu52E2TbsD6({<_%:;G3gfA**Ew=7yq$I&\~_\F93%2?z?d#9paC}y0qv9dvHE%%u~@=>d?ax8r0D+=7)H&;y7'B'z+"vBH|uhCA<vxhx)y':brz7)q9rf5h#sCxh3zu?Gq20sfJt}@g%q}~Cwg'80q2td{q+%8TbsTbsU2>Aj6D966Eldc'cga_dU2>Aj?6HD:E6>:5la_ac'''b__bhc'U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEADTbpTauTauHHH]D:=6?46\E96C2A6FE:4D]4@>TauU2>Aj:?56IlaU2>Aj>5dl2ecg54e'h773g4e32'25eh'hhg6564daQ C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]D:=6?46\E96C2A6FE:4D]4@>^k^2m]k^AmkAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'''b__bhc'^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'''b__bhc'^6?^k^2mk^AmkAmr~}%pr%i $:=6?46 %96C2A6FE:4D A=4k^AmkAmv6> w@A<:?D[ '![ w625 @7 x# 2?5 r@CA@C2E6 r@>>F?:42E:@?Dk^Am kAmk2 9C67lQ>2:=E@i:CoD:=6?46\E96C2A6FE:4D]4@>Qm:CoD:=6?46\E96C2A6FE:4D]4@>k^2mk^AmkAm%6=i Z' WeceX ebf\ba_gk^AmkAmzt*(~#si t&#~!t x#t{p}s &}x%ts zx}vs~|k^AmkAmx}s&$%#* zt*(~#si wtp{%w vt}t%xr$ ~%wt# wtp{%w r{x}xrp{ %#xp{$ !wp#|prt&%xrp{ rp#sx~{~v*k^AmkAm$~&#rti $:=6?46 %96C2A6FE:4D A=4k^AmkAmr@AJC:89E qFD:?6DD (:C6 a_ac]k^AmkAm!&qi ''^'b^a_ac _gi__ p|^sx$ri ''^'b^a_ac _fidh p|k^AmkAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'''b__bhc'^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'''b__bhc'^6?k^2mk^Am